Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer: A Randomized Study

Jeremić, Branislav; Shibamoto, Yuta; Nikolic, Nebojsa; Miličić, Biljana; Milisavljević, Slobodan; Dagović, Aleksandar; Aleksandrovic, Jasna; Radosavljevic-Asic, G.

doi:10.1200/jco.1999.17.7.2092

Cited by 323 publications

(241 citation statements)

References 21 publications

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…We found that radiotherapy was associated with improved survival, which is consistent with previous studies. In a randomized trial, the combination of chemotherapy and thoracic radiotherapy compared with chemotherapy alone resulted in a median 5-year survival rate of 9.1% versus 3.7%, respectively, for patients with ES-SCLC (Jeremic et al, 1999). In another randomized study, prophylactic cranial irradiation reduced the risk of symptomatic brain metastases and also improved survival in patients with ES-SCLC (Slotman et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis

Wu¹,

Li²,

Jiao³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The objective of this retrospective study was to investigate prognostic factors associated with survival of patients with extensive stage small cell lung cancer (ES-SCLC). Included were 200 patients admitted to the Liberation Army General Hospital with a diagnosis of ES-SCLC. The demographics of patients, disease characteristics, pre-treatment biochemical parameters and therapeutic plan were assessed or evaluated. Univariate analysis found that second-line chemotherapy, radiotherapy, and no liver metastasis were associated with improved survival. Tumor response to first-line chemotherapy and normal initial hemoglobin levels were also associated with a survival benefit (all P-values ≤ 0.0369). Multivariate Cox regression analysis indicated that liver metastasis and the total number of all chemotherapy cycles were independent prognostic factors of survival. The morbidity risk in patients with liver metastasis was 2.52-fold higher than that in patients without liver metastasis (hazard ratio (HR)=2.52 (1.69-3.76); P<0.0001). However, one unit increase in the total number of chemotherapy cycles decreased the risk of death by 0.86-fold (HR=0.86 (0.80-0.92); P<0.0001). Absence of liver metastasis and ability of a patient to receive and tolerate multiple lines of chemotherapy were associated with longer survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis

Wu¹,

Li²,

Jiao³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The use of TRT in patients with a CR at distant sites gave rise to significant improvement of survival. Median survival was 17 months for patients who received TRT, compared to only 11 months for those who received chemotherapy alone (Jeremic et al, 1999). The 5-year survival rate was 9.1% for the TRT group and was 3.7% for the chemotherapy-only group (P = 0.041) (Jeremic et al, 1999).…”

Section: Role Of Radiotherapy In the Treatment Of Ed-sclcmentioning

confidence: 97%

“…Median survival was 17 months for patients who received TRT, compared to only 11 months for those who received chemotherapy alone (Jeremic et al, 1999). The 5-year survival rate was 9.1% for the TRT group and was 3.7% for the chemotherapy-only group (P = 0.041) (Jeremic et al, 1999). However, this one small-, single-center randomized study has not led to the routine use of TRT in ED-SCLC.…”

Section: Role Of Radiotherapy In the Treatment Of Ed-sclcmentioning

confidence: 99%

“…Patients (N = 109) with a complete response at distant sites and a complete or partial response in the thorax were randomized to either the chemotherapy alone group or the accelerated hyper-fractionated radiotherapy group. Patients received radiotherapy of 54 Gy in 36 fractions over 18 days along with carboplatin and topside (Jeremic et al, 1999). TRT was also given to all patients who had PR at distant sites, without randomization.…”

Section: Role Of Radiotherapy In the Treatment Of Ed-sclcmentioning

confidence: 99%

“…There is only one study that systematically addressed the role of TRT in patients with ED-SCLC. Jeremic et al (1999) treated 206 patients with 3 cycles of chemotherapy consisting of cisplatin and etoposide. Patients (N = 109) with a complete response at distant sites and a complete or partial response in the thorax were randomized to either the chemotherapy alone group or the accelerated hyper-fractionated radiotherapy group.…”

Section: Role Of Radiotherapy In the Treatment Of Ed-sclcmentioning

confidence: 99%

See 2 more Smart Citations

Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer

Wu¹,

Wang²,

Wang³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Small cell lung cancer (SCLC) is an aggressive disease, in which more than 80% of patients present distant metastases at the time of first diagnosis. Chemotherapy is considered as the main treatment of extensive disease of SCLC (ED-SCLC), while the role of radiotherapy in the treatment of ED-SCLC is controversial. A case-control study was undertaken of patients diagnosed as ED-SCLC between 2004 and 2010. Fifty-eight patients with overall survival (OS) over 1 year were chosen, and another 58 patients with OS less than 1 year were selected as the control group, with the age, gender, metastasis or no metastasis of the liver, and the response after the first line of chemotherapy matched. The 1-year, 2-year, 3-year, and median OS of the 75 ED-SCLC patients who received radiation were 81.47, 29.89, 22.77%, and 17 months, respectively, and were 61.18, 23.53, 0%, and 16 months, respectively, for patients who did not receive radiation. The χ 2 test and odds ratio (OR) estimate demonstrated that these differences were statistically significant (χ 2 = 6.38, P = 0.0116; OR = 2.74, 95% confidence interval = 1.24-6.05). These results show that radiotherapy also plays a role in responding patients with extensive stage of SCLC.

show abstract

Consolidative thoracic radiotherapy for extensive disease small cell lung cancer

Kim

Kang

Cha

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer: A Randomized Study

Abstract: The addition of ACC HFX RT to the treatment of the most favorable subset of patients led to improved survival over that obtained with CHT alone.

Cited by 323 publications

References 21 publications

Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis

Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis

Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer

Consolidative thoracic radiotherapy for extensive disease small cell lung cancer

Contact Info

Product

Resources

About